Lundbeck files app for alcohol dependence drug

Tools

Lundbeck has filed for European approval of Selincro, a new treatment for alcohol dependence. The Dutch company obtained the treatment in a 96 million euro licensing deal with Biotie. New late-stage data on the drug is due for release in March. "Existing drugs for alcohol dependence require abstinence, which is a very high treatment hurdle," says Biotie CEO Timo Veromaa. "Selincro provides a solution for patients by allowing them to take the drug on an as needed basis, leading to a reduction in their alcohol consumption and number of heavy drinking days." Release | Story